IO, Surabaya – Professor of the Sepuluh Nopember Institute of Technology (ITS), Surabaya, Riyanarto Sarno, has developed an innovative Covid-19 detection device, sensing the illness through the smell of underarm sweat; it is called “i-nose c-19”. Development of the software is based on artificial intelligence technology that has gone through Stage One clinical trials, and is led directly by this professor from the ITS Informatics Engineering Department; the project involves his students from master and doctoral levels.
It is said that the i-nose c-19 is the first Covid-19 screening tool in the world to detect illness through the axillary sweat odor. I-nose c-19 works by taking a sample of underarm sweat and processing it, using artificial intelligence (AI).
“Underarm sweat is non-infectious, which means that the i-nose c-19 waste and exhaust air does not contain the Covid-19 virus,” said Prof. Ryan, his nickname, in a release received by the Independent Observer, Saturday (16/1/2021).
The advantage of the i-nose c-19, including sampling and processing, is that it is in one tool so that the screening results can be seen immediately and thus guarantee a quicker process. “The i-nose c-19 device is equipped with near-field communication (NFC) features, so filling in data is accomplished simply by attaching an e-KTP (electronic ID-Ed.).”
The reliability of data in the i-nose c-19 is guaranteed because of its storage in the device or the cloud. The use of cloud computing supports the i-nose c-19, to be integrated with the public, patients, doctors, hospitals, and laboratories. “With various advantages, the i-nose C-19, the work of Indonesians, is here to answer the challenges of the uncontrolled Covid-19 pandemic,” he said.
Besides being guaranteed in terms of costs, because it uses cheap technological components, the i-nose c-19 also does not require special expertise in its implementation. This scanner can be used by anyone with a simpler safety device, namely only gloves and a mask as basic protection.
He explained that the i-nose c-19 was the result of a four-year study which was then optimized by working with the Covid-19 virus since March 2019. Currently, the i-nose c-19 has reached Phase One clinical trial. “In the future, sampling data will be improved to get distribution permits, so that they can be commercialized for the public,” said the ITS Informatics Engineering lecturer.
Prof. Ryan hopes that the i-nose c-19 can be commercialized in a maximum of three months, “Seeing the increasing spread of the Covid-19 virus, the world needs a lot of screening technologies that are easy and quick to implement.” (est)